Triple Negative Breast Cancer in People of North East India: Critical Insights Gained at a Regional Cancer Centre |
Sharma, Mousumi
(Pathology, Dr. B. Borooah Cancer Institute)
Sharma, Jagannath Dev (Pathology, Dr. B. Borooah Cancer Institute) Sarma, Anupam (Pathology, Dr. B. Borooah Cancer Institute) Ahmed, Shiraj (Pathology, Dr. B. Borooah Cancer Institute) Kataki, Amal Chandra (Medical Director, Dr. B. Borooah Cancer Institute) Saxena, Rahul (Biochemistry, SMSR, Sharda University) Sharma, Dilutpal (Biochemistry, SMSR, Sharda University) |
1 | Ambroise M, Ghosh M, Mallikarjuna VS, Kurian M (2011). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev, 12, 625-9. |
2 | Basu S, Chen W, Tchou J, et al (2008). Comparison of triple negative and estrogen receptor positive/progesterone receptor positive/HER 2 negative breast carcinoma using quantitative fluorine-18 flurodeoxyglucose/positron emission tomography imaging parameters: a potentially usefull method for disease characterization. Cancer, 112, 995-1000. DOI ScienceOn |
3 | Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so called triple-negative phenotype. Cancer, 109, 1721-8. DOI ScienceOn |
4 | Carey LA, Perou CM, Livsay CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA, 295, 2492-502. DOI ScienceOn |
5 | Dolle JM, Dating JR, White E, et al (2009). Risk factors for TNBC in women Under age 45. Cancer Epidemiol Biomarkers Prev, 18, 1157-66. DOI ScienceOn |
6 | Cheang M, Voduc D, Bajdik C (2008). Basal- like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin cancer Res, 14, 1368-76. DOI ScienceOn |
7 | Chutstecka Z (2008). Survival Disadvantage Seen for TNBC. Medscape Medical News. |
8 | Cummings MC, Chamber R, Simpson PT, Lakhani SR. (2011). Molecular classification of breast carcinoma. Is it time to pack up our microscopes? Pathology, 43, 1-8. DOI ScienceOn |
9 | Foulkes WD, Stefanson IM, Chappuis PO, et al (2003). Germline BRCA1 mutation and a basal epithelial phenotype breast cancer. J Nath Cancer Inst, 95, 1482-5. DOI ScienceOn |
10 | Gown AM (2008). Current issue in ER and HER2/neu testing by IHC in breast cancer. Mod Pathol, 21, 8-15. DOI |
11 | Hammond ME, Haydes DF, Dowsett M, et al (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 28, 2784-95. DOI ScienceOn |
12 | Huang HJ, Neven P, Drijkoningen M, et al (2005). Association between tumour characteristics and HER2/NEU by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol, 58, 611-6. DOI ScienceOn |
13 | Hudis CA, Gianni L (2011). Triple negative breast cancer. An unmet medical need. Oncologist, 16, 1-11. |
14 | Luo X, Shi YX, Li ZM, Jiang WQ (2010). Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer, 29, 585-90. DOI |
15 | Iwase H, Kurebayashi J, Tsuda H, et al (2010). Clinicopathological registration committee of the Japanese breast cancer society. Breast Cancer, 17, 118. DOI ScienceOn |
16 | Li CY, Zhang S, Zhang XB, et al (2013). Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev, 14, 3779-84. 과학기술학회마을 DOI ScienceOn |
17 | Lund MJ, Triver KF, Porter PL, et al (2009). Race and triple negative threats to breast cancer survival: a population based study in Atlanta, GA. Breast Cancer Res Treat, 113, 357-70. DOI ScienceOn |
18 | National Cancer Registry Programme (NRCP). Three year Report of Population Based Cancer Registries, 2009-2011. (ICMR); Bangalore Pg 55. |
19 | Ma KK, Chau WW, Wong CH, et al (2013). Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev, 13, 2109-14. 과학기술학회마을 DOI ScienceOn |
20 | Moore MA, Ariyaratne Y, Badar F, et al (2010). Cancer epidemiology in South Asia- past , present and future. Asian Pac J Cancer Prev, 11, 49-66. |
21 | Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res, 7, 4-13. DOI |
22 | Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S (1995). Natural history of node negative breast cancer, a study of 826 patients with long term follow up. J Clin Oncol, 13, 1144-51. |
23 | Somali I, Ustaoglu BY, Tarhan MO, et al (2013). Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience. Asian Pac J Cancer Prev, 14, 6013-7. 과학기술학회마을 DOI ScienceOn |
24 | Reynolds S (2007). Spotlight: triple -negative breast carcinoma disproportionately affects African American and hispanic women. NCI Cancer Bulletin, 4, 22. |
25 | Ross JS, Fletcher JA, Linette GP, et al (2003). The HER2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist, 8, 307-25. DOI ScienceOn |
26 | Sotriou C, Neo S, McShane, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Nat Acad Sci USA, 100, 10393-8. DOI ScienceOn |
27 | Routa S, Jayashree R (2013). Study of ER, PR and HER2 neu on malignant breast lesions and correlation with other prognostic parameters, Int J Gen Med Pharma, 1, 1-8. |
28 | Sorlie T, Perou CM, Fan C, et al (2006). Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther, 5, 2914-8. DOI |
29 | Sorlie T, Tibshirani R, Hasie T, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Nact Acad Sci USA, 100, 8418-23. DOI ScienceOn |
30 | Takier R, Srivastav A (2008). Time trend in breast and cervix cancer of women in India (1990-2003). Asian Pac J Cancer Prev, 9, 777-80. |
31 | Tischkowitz M, Brunet JS, Begin LR, et al (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7, 134. DOI |
32 | Wolff A, Hammond ME, Schwartz J, et al (2007). American society of clinical oncology/CAP guideline recommendation for human epidermal growth factor receptor testing in breast carcinoma. J Clin Oncol, 25, 118-45. |
33 | Zafrani B, Leryoer A, Fourquet A, et al (2000). Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erb-B2 protein and proliferative activity. Semn Diagn Pathol, 11, 208-14. |
34 | Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52. DOI ScienceOn |
35 | Zubeda S, Kaipa PR, Shaik NA, et al (2013). HER-2/neu status: a neglected marker of breast cancer patients in India. Asian Pac J Cancer Prev, 14, 2231-5. 과학기술학회마을 DOI ScienceOn |
36 | Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v 1.0, Cancer incidence and Mortality Worldwide: IARC Cancer Base No.11[Internet]. Lyon, France: International Agency for Research on Cancer, 2013. Available from http: //globocan, iarc.fr. |